title: One-year treatment outcomes of ziv-aflibercept for treatment-naïve macular oedema in branch retinal vein occlusion.
authors.affiliation: Montreal Retina Institute, Montreal, QC, Canada.|Department of Ophthalmology, McGill University, Montreal, QC, Canada.
authors.forename: Errol W
authors.identifier: 0000-0002-9055-4802
authors.initials: EW
authors.lastname: Chan
authors.affiliation: Montreal Retina Institute, Montreal, QC, Canada.
authors.forename: Mohab
authors.initials: M
authors.lastname: Eldeeb
authors.affiliation: Smt Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India.
authors.forename: Chintan J
authors.initials: CJ
authors.lastname: Dedhia
authors.affiliation: Department of Ophthalmology, American University of Beirut, Beirut, Lebanon.|Department of Ophthalmology, Rafic Hariri University Hospital, Beirut, Lebanon.
authors.forename: Ahmad
authors.initials: A
authors.lastname: Mansour
authors.affiliation: Smt Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India.
authors.forename: Jay
authors.identifier: 0000-0003-1772-3558
authors.initials: J
authors.lastname: Chhablani
mesh_terms: D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000473:pathology*; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D013997:Time Factors; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor